BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, expanding its presence in rare metabolic diseases.
In this article
BioMarin Pharmaceutical
said on Friday it would acquire Amicus Therapeutics
for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock’s last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio of rare-disease…
The Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1 billion.
Neurocrine has offered $53 per Soleno share held, which represents a premium of about 34% to the stock's last close.
L’operazione, che riguarda una società specializzata nelle malattie rare, è la più grande acquisizione realizzata sotto la guida…
Boston Scientific said on Thursday it will buy medtech firm Penumbra in a deal valued at about $14.5 billion to expand its…
L’intesa prevede il pagamento agli azionisti della biotech di 129 dollari per azione, con un premio del 27% rispetto al prezzo di…
